Precigen, Inc. (PGEN): Revenue
$9.68M
Year ended 2025-12-31
$85.72M
Trailing 12 months to 2026-06-30
-28.9%
3-year compound annual growth
-21.3%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.68M | +146.7% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $3.92M | -36.9% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $6.22M | -76.9% | 2026-03-25, From 2023-01-01 |
| 2022-12-31 | $26.91M | +88.6% | 2023-03-06, From 2022-01-01 |
| 2021-12-31 | $14.27M | -55.4% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $31.99M | -64.7% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $90.72M | -40.0% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $151.18M | -31.1% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $219.46M | n/c | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $190.93M | +10.0% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $173.60M | +141.4% | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | $71.93M | +202.7% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $23.76M | +72.5% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $13.77M | +71.9% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $8.01M | n/a | 2014-03-31, From 2011-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Precigen, Inc. (PGEN) | 2025-12-31 | $9.68M | +146.7% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $9.68M | -92.8% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $10.00M | -5.6% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $10.00M | +100.0% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $9.10M | +0.2% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $8.99M | n/a |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $10.84M | n/a |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.26M | -71.6% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $11.51M | -1.5% |
Compare PGEN, PRTA, JANX, ZBIO side by side · Screen every company in Pharmaceutical Preparations ↗